Genelux

Genelux P/B

The P/B (Price-to-Book Ratio) of Genelux (GNLX) as of Nov 3, 2026 is 10.11. In the previous year, P/B (Price-to-Book Ratio) was 4.44 — a change of 127.60% (higher).

P/B

10.11

YoY

127.60%

Last updated:

P/B (Price-to-Book Ratio) of Genelux is 2025 10.11 . P/B (Price-to-Book Ratio) of Genelux was 2024 4.44 . It decreases by 127.60% higher compared to the previous year.

The Genelux P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2019
-4.70 USD
Jan 1, 2020
-5.15 USD
Jan 1, 2021
-3.52 USD
Jan 1, 2022
-3.26 USD
Jan 1, 2023
5.99 USD
Jan 1, 2024
4.44 USD
Jan 1, 2025
10.11 USD
The Genelux P/B history
YEARP/BYoY
10.11+127.60%
4.44-25.88%
5.99-283.76%
-3.26-7.47%
-3.52-31.58%
-5.15+9.52%
-4.70—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genelux Stock analysis

What does Genelux do? Genelux Corp develops and markets oncolytic viral immunotherapies, including Olvi-Vec, a modified vaccinia virus strain for platinum-resistant ovarian cancer, and V2ACT, a personalized anti-cancer therapy enhancing T cell activity. The company focuses on Phase II trials for Olvi-Vec in solid tumors and offers V-VET1, a veterinary oncolytic virus for animal health. Products target patients with solid tumor types and animal health applications, with clinical development driven by the firm's pipeline. The company generates revenue through the development and commercialization of its drug candidates, including Olvi-Vec, V2ACT, and V-VET1, targeting both human oncology and veterinary markets. Clinical trial phases and product development stages define its current focus, with Olvi-Vec in Phase II for ovarian cancer and V-VET1 in veterinary applications. The firm operates with a 15-employee structure, emphasizing pipeline advancement without publicized commercial sales yet. Genelux Corp's product portfolio includes Olvi-Vec for human solid tumors, V2ACT as a personalized immunotherapy, and V-VET1 for animal health. The company's revenue model relies on advancing these therapies through clinical trials, with no current commercial sales disclosed. The firm is positioned to address unmet needs in oncology, particularly in platinum-resistant cancers, and veterinary oncology through its viral-based approaches. Genelux is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genelux stock

P/B (Price-to-Book Ratio) of Genelux is 10.11 in 2025.

P/B (Price-to-Book Ratio) of Genelux changed from 4.44 to 10.11, representing a 127.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Genelux since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Genelux with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Genelux

All Key Metrics — Genelux